WallStSmart

Evolent Health Inc (EVH)vsVeeva Systems Inc Class A (VEEV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Veeva Systems Inc Class A generates 70% more annual revenue ($3.20B vs $1.88B). VEEV leads profitability with a 28.4% profit margin vs -28.5%. VEEV earns a higher WallStSmart Score of 69/100 (B-).

EVH

Hold

37

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 5.0Quality: 5.0
Piotroski: 3/9Altman Z: 0.03

VEEV

Strong Buy

69

out of 100

Grade: B-

Growth: 8.0Profit: 8.0Value: 9.3Quality: 7.8
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for EVH.

VEEVUndervalued (+25.9%)

Margin of Safety

+25.9%

Fair Value

$238.92

Current Price

$178.11

$60.81 discount

UndervaluedFair: $238.92Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EVH1 strengths · Avg: 10.0/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

VEEV6 strengths · Avg: 8.5/10
Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Profit MarginProfitability
28.4%9/10

Keeps 28 of every $100 in revenue as profit

PEG RatioValuation
0.868/10

Growing faster than its price suggests

Operating MarginProfitability
29.4%8/10

Strong operational efficiency at 29.4%

Revenue GrowthGrowth
16.0%8/10

16.0% revenue growth

EPS GrowthGrowth
23.2%8/10

Earnings expanding 23.2% YoY

Areas to Watch

EVH4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$288.03M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.293/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

VEEV1 concerns · Avg: 4.0/10
P/E RatioValuation
32.9x4/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : EVH

The strongest argument for EVH centers on Price/Book.

Bull Case : VEEV

The strongest argument for VEEV centers on Debt/Equity, Profit Margin, PEG Ratio. Profitability is solid with margins at 28.4% and operating margin at 29.4%. Revenue growth of 16.0% demonstrates continued momentum.

Bear Case : EVH

The primary concerns for EVH are EPS Growth, Market Cap, Debt/Equity.

Bear Case : VEEV

The primary concerns for VEEV are P/E Ratio.

Key Dynamics to Monitor

EVH profiles as a turnaround stock while VEEV is a growth play — different risk/reward profiles.

VEEV carries more volatility with a beta of 1.12 — expect wider price swings.

VEEV is growing revenue faster at 16.0% — sustainability is the question.

VEEV generates stronger free cash flow (100M), providing more financial flexibility.

Bottom Line

VEEV scores higher overall (69/100 vs 37/100), backed by strong 28.4% margins and 16.0% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Evolent Health Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Evolent Health, Inc., through its subsidiary, Evolent Health LLC, provides healthcare delivery and payment solutions in the United States. The company is headquartered in Arlington, Virginia.

Visit Website →

Veeva Systems Inc Class A

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, Asia Pacific, the Middle East, Africa, and Latin America. The company is headquartered in Pleasanton, California.

Visit Website →

Want to dig deeper into these stocks?